ABSTRACT

Buprenorphine and the Opioid Crisis: A Primer for Congress [December 7, 2018]   [open pdf - 1MB]

"Buprenorphine is one of three medications currently used in medication-assisted treatment of opioid use disorders. As such, buprenorphine's effectiveness, safety, and availability are of considerable interest to policymakers seeking to address the ongoing opioid crisis in the United States. During the 115th Congress, committees held hearings on opioid-related topics such as implementation of the Comprehensive Addiction and Recovery Act of 2016 (CARA, P.L. 114-198), the effects of the opioid crisis on families, and opioid use among veterans. Members have introduced more than 150 bills related to opioids. On October 24, 2018, President Trump signed into law H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (the SUPPORT Act; P.L. 115-271), a broad measure designed to address widespread over prescribing and abuse of opioids in the United States. Congressional actions taken in recent years to address the opioid crisis, including the SUPPORT Act, have included attempts to increase access to buprenorphine."

Report Number:
CRS Report for Congress, R45279
Author:
Publisher:
Date:
2018-12-07
Copyright:
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Format:
pdf
Media Type:
application/pdf
URL:
Help with citations